Boston Scientific’s Revenue Breakdown Worldwide (2018-2022)

This statistic highlights Boston Scientific’s Revenue Breakdown Worldwide, split across US, EMEA, APAC and LACA regions, reported on a quarterly basis from 2018 onwards.

Boston Scientific is a manufacturing company which aims to transform the lives and health of patients all over the world, by providing innovative medical solutions.

Boston Scientific’s Revenue Breakdown Worldwide

(All figures in billions, except percentages)

Boston Scientific’s total revenue grew from $2.59 billion in Q3 2020 to $2.93 billion in Q3 2021, registering a growth of 13.12% on a year-on-year basis. However, when compared on a quarter-on-quarter basis, it fell from $3.08 billion earned in Q2 2021 to $2.932 billion earned in Q3 2021, marking a decrease of 5%. This decrease is consistent across all its markets except LACA.

The US is the major contributor of revenue for the company, accounting for almost 59% of the total revenue in Q3 2021. It is followed by EMEA contributing 20%, APAC contributing 18% and LACA contributing 3% to the total revenue generated by Boston Scientific in Q3 2021.

Boston Sceintific’s revenue can be further bifurcated into the following regions:

U.S.

The United States is the largest market for the company, accounting for 59% of its total revenue generated in Q3 2021, amounting to $1.73 billion. It increased from $1.50 billion earned in Q3 2020 to $1.73 billion earned in Q3 2021, marking a growth of 15% on a year-on-year basis. However, it decreased from $1.80 billion earned in Q2 2021 to $1.73 billion earned in Q3 2021, marking a fall of 4% on a quarter-on-quarter basis.

EMEA

The EMEA region includes countries from Europe, Middle East and Africa. Europe, Middle East and Africa (EMEA) region accounts for 20% of the company’s total revenue, amounting to $0.59 billion in Q3 2021. It increased from $0.54 billion earned in Q3 2020 to $0.59 billion earned in Q3 2021, marking a growth of 9% on a year-on-year basis. However, it decreased from $0.66 billion earned in Q2 2021 to $0.59 billion earned in Q3 2021, marking a fall of 11% on a quarter-on-quarter basis.

APAC

APAC stands for Asia Pacific region, which includes South Asia, East Asia and Oceania. The Asia Pacific (APAC) region accounts for 18% of Boston Scientific’s total revenue, amounting to $1.73 billion in Q3 2021. It increased from $0.47 billion earned in Q3 2020 to $0.52 billion earned in Q3 2021, marking a growth of 10% on a year-on-year basis. However, it marginally decreased from $1.80 billion earned in Q2 2021 to $1.73 billion earned in Q3 2021, marking a fall of 1% on a quarter-on-quarter basis.

LACA

LACA stands for Latin America and Central America. The LACA region accounts for a very small fraction of Boston Scientific’s revenue, having a share of just 3% in the total revenue earned in Q3 2021, amounting to $0.099 billion. It increased from $0.077 billion earned in Q3 2020 to $0.099 billion earned in Q3 2021, marking a growth of 29% on a year-on-year basis. It also grew from $0.095 billion earned in Q2 2021 to $0.099 billion earned in Q3 2021, marking a rise of 4% on a quarter-on-quarter basis.

About Boston Scientific Corporation

Boston Scientific Corporation is a medical device manufacturer that specializes in interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology, and gynecology. The company heavily relies on Acquisitions and has acquired more than 40 companies since 2004. The company currently has 36,000 employees and is headquartered in Marlborough, Massachusetts, United States. Its employees have a very positive opinion of the company. Boston Scientific was placed 43rd out of 100 companies in the Glassdoor website’s 2019 Best Places to Work – Employees Choice Survey, with an average score of 4.3 out of 5 possible stars. Current and former employees provided input for this survey. Women make up 43 percent of Boston Scientific’s workforce, 38 percent of management jobs, and 23 percent of corporate top management positions.

The Taxus Stent, a drug-eluting stent intended to unblock clogged arteries, is one of Boston Scientific’s most well-known products. Cameron Health became known for delivering a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM, a subcutaneous implantable defibrillator (S-ICD) when it was fully acquired in June 2012. The company is currently traded on the New York Stock Exchange (NYSE) with the ticker ‘BSX’ and is a component of the S&P 500 Index. 

Did you like Boston Scientific’s Revenue Breakdown Worldwide statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.